ABN-Amro is continuing to recommend Galen Pharmaceuticals for investors. The company is continuing to deliver an established strategy of earnings growth and high investment in the development of proprietary products. Its full-year results were ahead of expectations with operating profit growth expected to run at a lower rate over the next couple of years. ABN-Amro says Galen must now focus on building an international business.